HolderBook

Pivotal bioVenture Partners Investment Advisor LLC

Reported holdings as of Q2 2026, from 23 quarterly filings.

CIK
1844645
Reported value
$307.8M
Positions
13
Top 10 weight
95.1%
Filed
2026-08-13
Days after quarter end
44

Holdings

SecurityTickerValue SharesWeightWeight change Held Change
VAXCYTE INCPCVX$82.9M1,425,47026.92%-1.58pp23q+3.9%+$3.1M
ARCUTIS BIOTHERAPEUTICS INCARQT$33.2M1,265,28310.78%-0.64pp23q-6.7%-$2.4M
TREVI THERAPEUTICS INCTRVI$32.5M1,742,67210.56%+3.93pp5q+12.2%+$3.5M
AVALYN PHARMACEUTICALS INCAVLN$31.8M966,79210.34%-newNEW
EVOMMUNE INCEVMN$25.6M1,926,9438.32%-7.51pp3qHELD
MAPLIGHT THERAPEUTICS INCMPLT$21.9M611,4467.12%+2.68pp3qHELD
OCULIS HOLDING AGOCS$20.9M1,506,2506.79%-9.18pp14q-10.4%-$2.4M
BIOAGE LABS INCBIOA$16.0M653,3745.20%+1.12pp8qHELD
IMMUNOME INCIMNM$15.5M732,5125.04%-0.68pp4qHELD
ZENAS BIOPHARMA INCZBIO$12.5M490,7664.05%-0.09pp8q-17.1%-$2.6M
AVALO THERAPEUTICS INCAVTX$8.0M434,0332.61%+1.03pp2q+46.7%+$2.6M
RALLYBIO CORPRLYB$4.8M300,5791.56%+0.60pp2qHELD
RECURSION PHARMACEUTICALS INRXRX$2.2M595,5180.71%+0.06pp7qHELD

By sector

Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.

Biotech & Pharma 89.7%Not classified 10.3%
 
SectorValueShare
Biotech & Pharma$276.0M89.7%
Not classified$31.8M10.3%

Quarter by quarter

QuarterValuePositions NewAddedTrimmed ExitedTop 10 Days to file
Q2 2026$307.8M13133195.1%44
Q1 2026$279.8M13213198.3%44
Q4 2025$258.7M12213099.2%44
Q3 2025$173.0M101203100.0%44
Q2 2025$161.3M12220199.2%44
Q1 2025$123.6M11020099.4%44
Q4 2024$148.1M11140199.5%44
Q3 2024$168.5M11211199.5%44
Q2 2024$130.1M100101100.0%44
Q1 2024$155.6M11012299.5%44
Q4 2023$394.2M13011099.0%44
Q3 2023$250.7M13221098.5%44
Q2 2023$303.3M11030099.8%42
Q1 2023$242.9M11120099.7%42
Q4 2022$230.0M100111100.0%44
Q3 2022$273.7M11002099.7%41
Q2 2022$198.5M11023099.5%43
Q1 2022$211.3M11100099.1%43
Q4 2021$239.2M101010100.0%45
Q3 2021$282.9M91000100.0%46
Q2 2021$253.7M80011100.0%47
Q1 2021$311.7M91031100.0%44
Q4 2020$303.3M90000100.0%40

Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.

Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.

Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.